Correlation Between Fate Therapeutics and Viridian Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Fate Therapeutics and Viridian Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Fate Therapeutics and Viridian Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Fate Therapeutics and Viridian Therapeutics, you can compare the effects of market volatilities on Fate Therapeutics and Viridian Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Fate Therapeutics with a short position of Viridian Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Fate Therapeutics and Viridian Therapeutics.

Diversification Opportunities for Fate Therapeutics and Viridian Therapeutics

0.76
  Correlation Coefficient

Poor diversification

The 3 months correlation between Fate and Viridian is 0.76. Overlapping area represents the amount of risk that can be diversified away by holding Fate Therapeutics and Viridian Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Viridian Therapeutics and Fate Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Fate Therapeutics are associated (or correlated) with Viridian Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Viridian Therapeutics has no effect on the direction of Fate Therapeutics i.e., Fate Therapeutics and Viridian Therapeutics go up and down completely randomly.

Pair Corralation between Fate Therapeutics and Viridian Therapeutics

Given the investment horizon of 90 days Fate Therapeutics is expected to under-perform the Viridian Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Fate Therapeutics is 1.15 times less risky than Viridian Therapeutics. The stock trades about -0.19 of its potential returns per unit of risk. The Viridian Therapeutics is currently generating about 0.04 of returns per unit of risk over similar time horizon. If you would invest  1,785  in Viridian Therapeutics on October 14, 2024 and sell it today you would earn a total of  35.00  from holding Viridian Therapeutics or generate 1.96% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Fate Therapeutics  vs.  Viridian Therapeutics

 Performance 
       Timeline  
Fate Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Fate Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain rather sound which may send shares a bit higher in February 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.
Viridian Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of conflicting performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Fate Therapeutics and Viridian Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Fate Therapeutics and Viridian Therapeutics

The main advantage of trading using opposite Fate Therapeutics and Viridian Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Fate Therapeutics position performs unexpectedly, Viridian Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Viridian Therapeutics will offset losses from the drop in Viridian Therapeutics' long position.
The idea behind Fate Therapeutics and Viridian Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Other Complementary Tools

Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities